Literature DB >> 16390501

Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia.

Stephen D Persell1, Donald M Lloyd-Jones, David W Baker.   

Abstract

BACKGROUND: Modifications to the National Cholesterol Education Program (NCEP) guidelines lowered optional low-density lipoprotein cholesterol (LDL-C) treatment goals.
OBJECTIVE: We evaluated the implications of widely adopting these optional goals in clinical practice. DESIGN AND PARTICIPANTS: We performed a cross-sectional study using 1999 to 2002 data from 3,281 U.S. adults aged 20 to 79 years participating the National Health and Nutrition Examination Survey. MEASUREMENTS: The primary outcomes were the proportions of adults whose fasting LDL-C levels exceeded NCEP recommended and optional targets from 2001 and 2004. We used survey weights to estimate the size of the U.S. population exceeding targets. We examined outcomes for 4 coronary disease risk subgroups described by the NCEP.
RESULTS: Low-density lipoprotein cholesterol values exceeded 2001 NCEP goals for 30.0% of adults, and 35.8% had levels above optional 2004 goals. An estimated 24,900,000 individuals (14.2%) exceeded 2001 thresholds for drug therapy, 46,200,000 (26.3%) exceeded optional 2001 thresholds for drug therapy, and 56,500,000 (32.2%) were above the optional 2004 thresholds for drug therapy. For lower, moderate, moderately high, and high-risk groups, 13.4%, 44.2%, 58.8%, and 71.8%, respectively, exceeded 2001 NCEP goals; 13.4%, 15.7%, 87.4%, and 96.0% of these groups exceeded optional 2004 thresholds for drug therapy.
CONCLUSIONS: In 1999 to 2002, LDL-C levels commonly exceeded 2001 NCEP goals, especially for moderately high and high-risk individuals, and cholesterol-lowering medications were underused. Optional goals promulgated by the NCEP in 2001 and 2004 moderately increased the number of adults with LDL-C above their goal, and greatly increased the number of low, moderately high, and high-risk adults who exceeded LDL-C thresholds, for cholesterol-lowering medication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16390501      PMCID: PMC1484657          DOI: 10.1111/j.1525-1497.2006.00323.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  32 in total

Review 1.  Economics of drug treatment: for which patients is it costeffective to lower cholesterol?

Authors:  B Jönsson
Journal:  Lancet       Date:  2001-10-13       Impact factor: 79.321

2.  Plasma lipid and lipoprotein responses to dietary fat and cholesterol: a meta-analysis.

Authors:  W H Howell; D J McNamara; M A Tosca; B T Smith; J A Gaines
Journal:  Am J Clin Nutr       Date:  1997-06       Impact factor: 7.045

3.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

Authors:  B Pitt; D Waters; W V Brown; A J van Boven; L Schwartz; L M Title; D Eisenberg; L Shurzinske; L S McCormick
Journal:  N Engl J Med       Date:  1999-07-08       Impact factor: 91.245

4.  Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease.

Authors:  A D Federman; A S Adams; D Ross-Degnan; S B Soumerai; J Z Ayanian
Journal:  JAMA       Date:  2001-10-10       Impact factor: 56.272

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.

Authors:  David J Graham; Judy A Staffa; Deborah Shatin; Susan E Andrade; Stephanie D Schech; Lois La Grenade; Jerry H Gurwitz; K Arnold Chan; Michael J Goodman; Richard Platt
Journal:  JAMA       Date:  2004-11-22       Impact factor: 56.272

7.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

Review 9.  Maximizing the cost-effectiveness of lipid-lowering therapy.

Authors:  T A Jacobson; J R Schein; A Williamson; C M Ballantyne
Journal:  Arch Intern Med       Date:  1998-10-12

10.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

View more
  8 in total

1.  Adherence of hospital-based cardiologists to lipid guidelines in patients at high risk for cardiovascular events (2L registry).

Authors:  Anselm K Gitt; Claus Jünger; Christina Jannowitz; Barbara Karmann; Jochen Senges; Kurt Bestehorn
Journal:  Clin Res Cardiol       Date:  2010-10-21       Impact factor: 5.460

2.  Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults: findings from the National Health and Nutrition Examination Survey 2003 to 2006.

Authors:  Amanda K Marma; Jarett D Berry; Hongyan Ning; Stephen D Persell; Donald M Lloyd-Jones
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2009-11-16

3.  Coronary risk assessment by point-based vs. equation-based Framingham models: significant implications for clinical care.

Authors:  William J Gordon; Jesse M Polansky; W John Boscardin; Kathy Z Fung; Michael A Steinman
Journal:  J Gen Intern Med       Date:  2010-09-08       Impact factor: 5.128

4.  Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany.

Authors:  Anselm K Gitt; Claus Jünger; Wenefrieda Smolka; Kurt Bestehorn
Journal:  Clin Res Cardiol       Date:  2010-06-03       Impact factor: 5.460

Review 5.  Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies.

Authors:  S Mitchell; S Roso; M Samuel; M Pladevall-Vila
Journal:  BMC Cardiovasc Disord       Date:  2016-04-26       Impact factor: 2.298

6.  Association of Metabolic Syndrome and Its Components with Survival of Older Adults.

Authors:  Ali Bijani; Seyed Reza Hosseini; Reza Ghadimi; Simin Mouodi
Journal:  Int J Endocrinol Metab       Date:  2020-01-28

7.  High Prevalence of Metabolic Syndrome and Its Related Demographic Factors in North of Iran: Results from the PERSIAN Guilan Cohort Study.

Authors:  Mohammadreza Naghipour; Farahnaz Joukar; Hossein-Ali Nikbakht; Soheil Hassanipour; Mehrnaz Asgharnezhad; Morteza Arab-Zozani; Fariborz Mansour-Ghanaei
Journal:  Int J Endocrinol       Date:  2021-03-29       Impact factor: 3.257

8.  Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients.

Authors:  Kenneth A Lichtenstein; Carl Armon; Kate Buchacz; Joan S Chmiel; Kern Buckner; Ellen Tedaldi; Kathleen Wood; Scott D Holmberg; John T Brooks
Journal:  Prev Chronic Dis       Date:  2013       Impact factor: 2.830

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.